Five potential therapeutic agents as antidepressants: a brief review and future directions

References

• Kessler RC, Petukhova M, Sampson NA, et al. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res 2012;21(3):169-84
   PubMed Web of Science ®Google Scholar
• Kulkarni SK, Dhir A. Current investigational drugs for major depression. Expert Opin Investig Drugs 2009;18(6):767-88
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163(11):1905-17
   PubMed Web of Science ®Google Scholar
• van Praag HM. Neuroendocrine disorders in depressions and their significance for the monoamine hypothesis of depression. Acta Psychiatr Scand 1978;57(5):389-404
   PubMed Web of Science ®Google Scholar
• Massart R, Mongeau R, Lanfumey L. Beyond the monoaminergic hypothesis: neuroplasticity and epigenetic changes in a transgenic mouse model of depression. Philos Trans R Soc Lond B Biol Sci 2012;367(1601):2485-94
   PubMed Web of Science ®Google Scholar
• OF OL, Dinan TG, Cryan JF. Faster, better, stronger: Towards new antidepressant therapeutic strategies. Eur J Pharmacol 2015;753:32-50
   PubMed Web of Science ®Google Scholar
• Dale E, Bang-Andersen B, Sanchez C. Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs. Biochem Pharmacol 2015;95(2):81-97
   PubMed Web of Science ®Google Scholar
• Artigas F. Serotonin receptors involved in antidepressant effects. Pharmacol Ther 2013;137(1):119-31
   PubMed Web of Science ®Google Scholar
• Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord 2013;15(1):1-44
   PubMed Web of Science ®Google Scholar
• Pae CU, Wang SM, Han C, et al. Vortioxetine: a meta-analysis of 12 short-term, randomised, placebo-controlled clinical trials for the treatment of major depressive disorder. J Psychiatry Neurosci 2015;40(3):174-86
   PubMed Web of Science ®Google Scholar
• Clinical Trials. Available from: https://clinicaltrials.gov/
   Google Scholar
• Development & Approval Process (Drugs). Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/
   Google Scholar
• Available from: https://www.fda.gov
   Google Scholar
• Jones LL, McDonald DA, Borum PR. Acylcarnitines: role in brain. Prog Lipid Res 2010;49(1):61-75
   PubMed Web of Science ®Google Scholar
• Tempesta E, Casella L, Pirrongelli C, et al. L-acetylcarnitine in depressed elderly subjects. A cross-over study vs placebo. Drugs Exp Clin Res 1987;13(7):417-23
   PubMedGoogle Scholar
• Wang SM, Han C, Lee SJ, et al. A review of current evidence for acetyl-l-carnitine in the treatment of depression. J Psychiatr Res 2014;53:30-7
   PubMed Web of Science ®Google Scholar
• Nasca C, Xenos D, Barone Y, et al. L-acetylcarnitine causes rapid antidepressant effects through the epigenetic induction of mGlu2 receptors. Proc Natl Acad Sci U S A 2013;110(12):4804-9
   PubMed Web of Science ®Google Scholar
• Di Cesare Mannelli L, Ghelardini C, Toscano A, et al. The neuropathy-protective agent acetyl-L-carnitine activates protein kinase C-gamma and MAPKs in a rat model of neuropathic pain. Neuroscience 2010;165(4):1345-52
   PubMed Web of Science ®Google Scholar
• Di Cesare Mannelli L, Vivoli E, Salvicchi A, et al. Antidepressant-like effect of artemin in mice: a mechanism for acetyl-L-carnitine activity on depression. Psychopharmacology (Berl) 2011;218(2):347-56
   PubMed Web of Science ®Google Scholar
• Smeland OB, Meisingset TW, Borges K, et al. Chronic acetyl-L-carnitine alters brain energy metabolism and increases noradrenaline and serotonin content in healthy mice. Neurochem Int 2012;61(1):100-7
   PubMed Web of Science ®Google Scholar
• Pettegrew JW, Levine J, McClure RJ. Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer’s disease and geriatric depression. Mol Psychiatry 2000;5(6):616-32
   PubMed Web of Science ®Google Scholar
• Alves E, Binienda Z, Carvalho F, et al. Acetyl-L-carnitine provides effective in vivo neuroprotection over 3,4-methylenedioximethamphetamine-induced mitochondrial neurotoxicity in the adolescent rat brain. Neuroscience 2009;158(2):514-23
   PubMed Web of Science ®Google Scholar
• Levine J, Kaplan Z, Pettegrew JW, et al. Effect of intraperitoneal acetyl-L-carnitine (ALCAR) on anxiety-like behaviours in rats. Int J Neuropsychopharmacol 2005;8(1):65-74
   PubMed Web of Science ®Google Scholar
• Villardita C SP, Vecchio I. Acetyl-l-carnitine in depressed geriatric patients. Eur Rev Med Pharmacol Sci 1993;6:1-12
   Google Scholar
• Nasca D ZG, Aguglia E. Action of acetyl-l-carnitine in association with mianserine on depressed old people. New Trends Clin Neuropharmacol 1989;3:225-30
   Google Scholar
• Garzya G, Corallo D, Fiore A, et al. Evaluation of the effects of L-acetylcarnitine on senile patients suffering from depression. Drugs Exp Clin Res 1990;16(2):101-6
   PubMedGoogle Scholar
• Gecele M FG, Meluzzi A. Acetyl-l-carnitine in aged subjects with major depression: clinical efficacy and effects on the circadian rhythm of cortisol. Dementia 1991;2:333-7
   Google Scholar
• Brennan BP, Jensen JE, Hudson JI, et al. A Placebo-controlled trial of acetyl-L-carnitine and alpha-lipoic acid in the treatment of bipolar depression. J Clin Psychopharmacol 2013;33(5):627-35
   PubMed Web of Science ®Google Scholar
• Bella R, Biondi R, Raffaele R, et al. Effect of acetyl-L-carnitine on geriatric patients suffering from dysthymic disorders. Int J Clin Pharmacol Res 1990;10(6):355-60
   PubMedGoogle Scholar
• Fulgente T OM, Del Re ML, Ferracci F, et al. Laevo-acetylcarnitine (NicetileR) treatment of senile depression. Journal of the Society for Clinical Trials 1990;27:155-63
   Google Scholar
• Zanardi R, Smeraldi E. A double-blind, randomised, controlled clinical trial of acetyl-L-carnitine vs. amisulpride in the treatment of dysthymia. Eur Neuropsychopharmacol 2006;16(4):281-7
   PubMed Web of Science ®Google Scholar
• Bersani G, Meco G, Denaro A, et al. l-Acetylcarnitine in dysthymic disorder in elderly patients: A double-blind, multicenter, controlled randomized study vs. fluoxetine. Eur Neuropsychopharmacol 2013;23(10):1219-25
   PubMed Web of Science ®Google Scholar
• Evans AM and Fornasini G. Pharmacokinetics of L-carnitine. Clin Pharmacokinet 2003;42(11):941-67
   PubMed Web of Science ®Google Scholar
• Shang R, Sun Z, Li H. Effective dosing of L-carnitine in the secondary prevention of cardiovascular disease: a systematic review and meta-analysis. BMC Cardiovasc Disord 2014;14:88
   PubMedGoogle Scholar
• Janowsky DS, el-Yousef MK, Davis JM, et al. A cholinergic-adrenergic hypothesis of mania and depression. Lancet 1972;2(7778):632-5
   PubMed Web of Science ®Google Scholar
• Chau D, Rada PV, Kosloff RA, et al. Cholinergic, M1 receptors in the nucleus accumbens mediate behavioral depression. A possible downstream target for fluoxetine. Ann N Y Acad Sci 1999;877:769-74
   PubMed Web of Science ®Google Scholar
• Hasselmann H. Scopolamine and depression: a role for muscarinic antagonism? CNS Neurol Disord Drug Targets 2014;13(4):673-83
   PubMed Web of Science ®Google Scholar
• Pae CU. Scopolamine as an antidepressant. Clin Neuropharmacol 2013;36(3):102
   PubMed Web of Science ®Google Scholar
• Jaffe RJ, Novakovic V, and Peselow ED. Scopolamine as an antidepressant: a systematic review. Clin Neuropharmacol 2013;36(1):24-6
   PubMed Web of Science ®Google Scholar
• Sanacora G, Treccani G, Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology 2012;62(1):63-77
   PubMed Web of Science ®Google Scholar
• Rami A, Ausmeir F, Winckler J, et al. Differential effects of scopolamine on neuronal survival in ischemia and glutamate neurotoxicity: relationships to the excessive vulnerability of the dorsoseptal hippocampus. J Chem Neuroanat 1997;13(3):201-8
   PubMed Web of Science ®Google Scholar
• Overstreet DH, Friedman E, Mathe AA, et al. The Flinders Sensitive Line rat: a selectively bred putative animal model of depression. Neurosci Biobehav Rev 2005;29(4-5):739-59
   PubMed Web of Science ®Google Scholar
• Newhouse PA, Sunderland T, Tariot PN, et al. The effects of acute scopolamine in geriatric depression. Arch Gen Psychiatry 1988;45(10):906-12
   PubMed Web of Science ®Google Scholar
• Gillin JC, Sutton L, Ruiz C, et al. The effects of scopolamine on sleep and mood in depressed patients with a history of alcoholism and a normal comparison group. Biol Psychiatry 1991;30(2):157-69
   PubMed Web of Science ®Google Scholar
• Furey ML, Drevets WC. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry 2006;63(10):1121-9
   PubMed Web of Science ®Google Scholar
• Drevets WC, Furey ML. Replication of scopolamine’s antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial. Biol Psychiatry 2010;67(5):432-8
   PubMed Web of Science ®Google Scholar
• Furey ML, Khanna A, Hoffman EM, et al. Scopolamine produces larger antidepressant and antianxiety effects in women than in men. Neuropsychopharmacology 2010;35(12):2479-88
   PubMed Web of Science ®Google Scholar
• Furey ML, Nugent AC, Speer AM, et al. Baseline mood-state measures as predictors of antidepressant response to scopolamine. Psychiatry Res 2012;196(1):62-7
   PubMed Web of Science ®Google Scholar
• Khajavi D, Farokhnia M, Modabbernia A, et al. Oral scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2012;73(11):1428-33
   PubMed Web of Science ®Google Scholar
• Janowsky DS. Serendipity strikes again: scopolamine as an antidepressant agent in bipolar depressed patients. Curr Psychiatry Rep 2011;13(6):443-5
   PubMedGoogle Scholar
• Spinks A, Wasiak J. Scopolamine (hyoscine) for preventing and treating motion sickness. Cochrane Database Syst Rev 2011(6):CD002851
   Google Scholar
• Drevets WC, Zarate CAJr, Furey ML. Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review. Biol Psychiatry 2013;73(12):1156-63
   PubMed Web of Science ®Google Scholar
• Bourre JM. [Omega-3 fatty acids in psychiatry]. Med Sci (Paris) 2005;21(2):216-21
   PubMed Web of Science ®Google Scholar
• Calder PC, Yaqoob P. Understanding omega-3 polyunsaturated fatty acids. Postgrad Med 2009;121(6):148-57
   PubMed Web of Science ®Google Scholar
• Su KP, Shen WW, Huang SY. Are omega3 fatty acids beneficial in depression but not mania? Arch.Gen.Psychiatry 2000;57(7):716-17
   PubMed Web of Science ®Google Scholar
• Su KP. Inflammation in psychopathology of depression: Clinical, biological, and therapeutic implications. Biomedicine 2012;2(2):68-74
   Google Scholar
• Su KP, Wang SM, Pae CU. Omega-3 polyunsaturated fatty acids for major depressive disorder. Expert Opin Investig Drugs 2013;22(12):1519-34
   PubMed Web of Science ®Google Scholar
• Grosso G, Galvano F, Marventano S, et al. Omega-3 fatty acids and depression: scientific evidence and biological mechanisms. Oxid Med Cell Longev 2014;2014:313570
   PubMed Web of Science ®Google Scholar
• Mischoulon D, Nierenberg AA, Schettler PJ, et al. A double-blind, randomized controlled clinical trial comparing eicosapentaenoic acid versus docosahexaenoic acid for depression. J Clin Psychiatry 2015;76(1):54-61
   PubMed Web of Science ®Google Scholar
• Dashti-Khavidaki S, Gharekhani A, Khatami MR, et al. Effects of omega-3 fatty acids on depression and quality of life in maintenance hemodialysis patients. Am J Ther 2014;21(4):275-87
   PubMed Web of Science ®Google Scholar
• Gharekhani A, Khatami MR, Dashti-Khavidaki S, et al. The effect of omega-3 fatty acids on depressive symptoms and inflammatory markers in maintenance hemodialysis patients: a randomized, placebo-controlled clinical trial. Eur J Clin Pharmacol 2014;70(6):655-65
   PubMed Web of Science ®Google Scholar
• Kaviani M, Saniee L, Azima S, et al. The effect of omega-3 fatty acid supplementation on maternal depression during pregnancy: a double blind randomized controlled clinical trial. Int J Community Based Nurs Midwifery 2014;2(3):142-7
   PubMedGoogle Scholar
• Su KP, Lai HC, Yang HT, et al. Omega-3 fatty acids in the prevention of interferon-alpha-induced depression: results from a randomized, controlled trial. Biol Psychiatry 2014;76(7):559-66
   PubMed Web of Science ®Google Scholar
• Lucas M, Asselin G, Merette C, et al. Ethyl-eicosapentaenoic acid for the treatment of psychological distress and depressive symptoms in middle-aged women: a double-blind, placebo-controlled, randomized clinical trial. Am J Clin Nutr 2009;89(2):641-51
   PubMed Web of Science ®Google Scholar
• Mischoulon D, Papakostas GI, Dording CM, et al. A double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive disorder. J Clin.Psychiatry 2009;70(12):1636-44
   PubMed Web of Science ®Google Scholar
• da Silva TM, Munhoz RP, Alvarez C, et al. Depression in Parkinson’s disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation. J Affect Disord 2008;111(2-3):351-9
   PubMed Web of Science ®Google Scholar
• Freeman MP, Davis M, Sinha P, et al. Omega-3 fatty acids and supportive psychotherapy for perinatal depression: a randomized placebo-controlled study. J Affect Disord 2008;110(1-2):142-8
   PubMed Web of Science ®Google Scholar
• Rees AM, Austin MP, Parker GB. Omega-3 fatty acids as a treatment for perinatal depression: randomized double-blind placebo-controlled trial. Aust N Z J Psychiatry 2008;42(3):199-205
   PubMed Web of Science ®Google Scholar
• Rogers PJ, Appleton KM, Kessler D, et al. No effect of n-3 long-chain polyunsaturated fatty acid (EPA and DHA) supplementation on depressed mood and cognitive function: a randomised controlled trial. BrJ Nutr 2008;99(2):421-31
   PubMed Web of Science ®Google Scholar
• Su KP, Huang SY, Chiu TH, et al. Omega-3 fatty acids for major depressive disorder during pregnancy: results from a randomized, double-blind, placebo-controlled trial. J.Clin.Psychiatry 2008;69(4):644-51
   PubMed Web of Science ®Google Scholar
• Nemets H, Nemets B, Apter A, et al. Omega-3 treatment of childhood depression: a controlled, double-blind pilot study. Am.J Psychiatry 2006;163(6):1098-100
   PubMed Web of Science ®Google Scholar
• Marangell LB, Martinez JM, Zboyan HA, et al. A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. Am J Psychiatry 2003;160(5):996-8
   PubMed Web of Science ®Google Scholar
• Jazayeri S, Tehrani-Doost M, Keshavarz SA, et al. Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder. Aust N Z J Psychiatry 2008;42(3):192-8
   PubMed Web of Science ®Google Scholar
• Su KP, Huang SY, Chiu CC, et al. Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. Eur Neuropsychopharmacol 2003;13(4):267-71
   PubMed Web of Science ®Google Scholar
• Peet M, Horrobin DF. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch.Gen.Psychiatry 2002;59(10):913-19
   PubMed Web of Science ®Google Scholar
• Silvers KM, Woolley CC, Hamilton FC, et al. Randomised double-blind placebo-controlled trial of fish oil in the treatment of depression. Prostaglandins Leukot Essent Fatty Acids 2005;72(3):211-18
   PubMed Web of Science ®Google Scholar
• Grenyer BF, Crowe T, Meyer B, et al. Fish oil supplementation in the treatment of major depression: a randomised double-blind placebo-controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 2007;31(7):1393-6
   PubMed Web of Science ®Google Scholar
• Carney RM, Freedland KE, Rubin EH, et al. Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease: a randomized controlled trial. JAMA 2009;302(15):1651-7
   PubMed Web of Science ®Google Scholar
• Bot M, Pouwer F, Assies J, et al. Eicosapentaenoic acid as an add-on to antidepressant medication for co-morbid major depression in patients with diabetes mellitus: a randomized, double-blind placebo-controlled study. J Affect Disord 2010;126(1-2):282-6
   PubMed Web of Science ®Google Scholar
• Lesperance F, Frasure-Smith N, St-Andre E, et al. The efficacy of omega-3 supplementation for major depression: a randomized controlled trial. J Clin Psychiatry 2011;72(8):1054-62
   PubMed Web of Science ®Google Scholar
• Gertsik L, Poland RE, Bresee C, et al. Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder. J Clin Psychopharmacol 2012;32(1):61-4
   PubMed Web of Science ®Google Scholar
• Sublette ME, Ellis SP, Geant AL, et al. Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression. J Clin.Psychiatry 2011;72(12):1577-84
   PubMed Web of Science ®Google Scholar
• Sarris J, Mischoulon D, Schweitzer I. Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression. J Clin.Psychiatry 2012;73(1):81-6
   PubMed Web of Science ®Google Scholar
• Martins JG. EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: evidence from a meta-analysis of randomized controlled trials. J Am Coll Nutr 2009;28(5):525-42
   PubMed Web of Science ®Google Scholar
• Lin PY, Su KP. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J Clin.Psychiatry 2007;68(7):1056-61
   PubMed Web of Science ®Google Scholar
• Kraguljac NV, Montori VM, Pavuluri M, et al. Efficacy of omega-3 fatty acids in mood disorders - a systematic review and metaanalysis. Psychopharmacol Bull 2009;42(3):39-54
   PubMed Web of Science ®Google Scholar
• Bloch MH, Hannestad J. Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis. Mol.Psychiatry 2011;17(12):1272-82
   PubMed Web of Science ®Google Scholar
• Appleton KM, Rogers PJ, Ness AR. Updated systematic review and meta-analysis of the effects of n-3 long-chain polyunsaturated fatty acids on depressed mood. Am J Clin Nutr 2010;91(3):757-70
   PubMed Web of Science ®Google Scholar
• Bays H. Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids. Am J Cardiol 2006;98(4A):71-6i
   PubMed Web of Science ®Google Scholar
• Trullas R, Skolnick P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol 1990;185(1):1-10
   PubMed Web of Science ®Google Scholar
• Aan Het Rot M, Zarate CAJr, Charney DS, et al. Ketamine for depression: where do we go from here? Biol Psychiatry 2012;72(7):537-47
   PubMed Web of Science ®Google Scholar
• Pochwat B, Palucha-Poniewiera A, Szewczyk B, et al. NMDA antagonists under investigation for the treatment of major depressive disorder. Expert Opin Investig Drugs 2014;23(9):1181-92
   PubMed Web of Science ®Google Scholar
• Sambataro F, Wolf ND, Pennuto M, et al. Revisiting default mode network function in major depression: evidence for disrupted subsystem connectivity. Psychol Med 2013;1-11
   Google Scholar
• Caddy C, Giaroli G, White TP, et al. Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy. Ther Adv Psychopharmacol 2014;4(2):75-99
   Google Scholar
• Yang C, Hu YM, Zhou ZQ, et al. Acute administration of ketamine in rats increases hippocampal BDNF and mTOR levels during forced swimming test. Ups J Med Sci 2013;118(1):3-8
   PubMed Web of Science ®Google Scholar
• Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000;47(4):351-4
   PubMed Web of Science ®Google Scholar
• Zarate CAJr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006;63(8):856-64
   PubMed Web of Science ®Google Scholar
• DiazGranados N, Ibrahim LA, Brutsche NE, et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry 2010;71(12):1605-11
   PubMed Web of Science ®Google Scholar
• Diazgranados N, Ibrahim L, Brutsche NE, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 2010;67(8):793-802
   PubMed Web of Science ®Google Scholar
• Ibrahim L, Diazgranados N, Luckenbaugh DA, et al. Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression. Prog Neuropsychopharmacol Biol Psychiatry 2011;35(4):1155-9
   PubMed Web of Science ®Google Scholar
• Kranaster L, Kammerer-Ciernioch J, Hoyer C, et al. Clinically favourable effects of ketamine as an anaesthetic for electroconvulsive therapy: a retrospective study. Eur Arch Psychiatry Clin Neurosci 2011;261(8):575-82
   PubMed Web of Science ®Google Scholar
• Yoosefi A, Sepehri AS, Kargar M, et al. Comparing effects of ketamine and thiopental administration during electroconvulsive therapy in patients with major depressive disorder: a randomized, double-blind study. J ECT 2014;30(1):15-21
   PubMed Web of Science ®Google Scholar
• Loo CK, Katalinic N, Garfield JB, et al. Neuropsychological and mood effects of ketamine in electroconvulsive therapy: a randomised controlled trial. J Affect Disord 2012;142(1-3):233-40
   PubMed Web of Science ®Google Scholar
• Price RB, Iosifescu DV, Murrough JW, et al. Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. Depress Anxiety 2014;31(4):335-43
   PubMed Web of Science ®Google Scholar
• Zarate CAJr, Brutsche NE, Ibrahim L, et al. Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 2012;71(11):939-46
   PubMed Web of Science ®Google Scholar
• Murrough JW, Iosifescu DV, Chang LC, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 2013;170(10):1134-42
   PubMed Web of Science ®Google Scholar
• Phelps LE, Brutsche N, Moral JR, et al. Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biol Psychiatry 2009;65(2):181-4
   PubMed Web of Science ®Google Scholar
• Valentine GW, Mason GF, Gomez R, et al. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. Psychiatry Res 2011;191(2):122-7
   PubMed Web of Science ®Google Scholar
• Ghasemi M, Kazemi MH, Yoosefi A, et al. Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder. Psychiatry Res 2014;215(2):355-61
   PubMed Web of Science ®Google Scholar
• Lapidus KA, Levitch CF, Perez AM, et al. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry 2014;76(12):970-6
   PubMed Web of Science ®Google Scholar
• De Luca MT, Meringolo M, Spagnolo PA, et al. The role of setting for ketamine abuse: clinical and preclinical evidence. Rev Neurosci 2012;23(5-6):769-80
   PubMed Web of Science ®Google Scholar
• Naughton M, Clarke G, O’Leary OF, et al. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action. J Affect Disord 2014;156:24-35
   PubMed Web of Science ®Google Scholar
• Irwin SA, Iglewicz A, Nelesen RA, et al. Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial. J Palliat Med 2013;16(8):958-65
   PubMed Web of Science ®Google Scholar
• Afridi SK, Giffin NJ, Kaube H, et al. A randomized controlled trial of intranasal ketamine in migraine with prolonged aura. Neurology 2013;80(7):642-7
   PubMed Web of Science ®Google Scholar
• Mnie-Filali O, Faure C, Lambas-Senas L, et al. Pharmacological blockade of 5-HT7 receptors as a putative fast acting antidepressant strategy. Neuropsychopharmacology 2011;36(6):1275-88
   PubMed Web of Science ®Google Scholar
• Nandam LS, Jhaveri D, Bartlett P. 5-HT7, neurogenesis and antidepressants: a promising therapeutic axis for treating depression. Clin Exp Pharmacol Physiol 2007;34(5-6):546-51
   PubMed Web of Science ®Google Scholar
• Kim Y, Tae J, Lee K, et al. Novel N-biphenyl-2-ylmethyl 2-methoxyphenylpiperazinylalkanamides as 5-HT7R antagonists for the treatment of depression. Bioorg Med Chem 2014;22(17):4587-96
   PubMed Web of Science ®Google Scholar
• Bonaventure P, Dugovic C, Kramer M, et al. Translational evaluation of JNJ-18038683, a 5-hydroxytryptamine type 7 receptor antagonist, on rapid eye movement sleep and in major depressive disorder. J Pharmacol Exp Ther 2012;342(2):429-40
   PubMed Web of Science ®Google Scholar
• Pae CU. The potential role of monocyte chemoattractant protein-1 for major depressive disorder. Psychiatry Investig 2014;11(3):217-22
   PubMed Web of Science ®Google Scholar
• Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010;67(5):446-57
   PubMed Web of Science ®Google Scholar
• Bay-Richter C, Linderholm KR, Lim CK, et al. A role for inflammatory metabolites as modulators of the glutamate N-methyl-D-aspartate receptor in depression and suicidality. Brain Behav Immun 2015;43:110-17
   PubMed Web of Science ®Google Scholar
• Pasquini M, Berardelli I, Biondi M. Ethiopathogenesis of depressive disorders. Clin Pract Epidemiol Ment Health 2014;10:166-71
   PubMedGoogle Scholar
• Blume J, Douglas SD, Evans DL. Immune suppression and immune activation in depression. Brain Behav Immun 2011;25(2):221-9
   PubMed Web of Science ®Google Scholar
• Kohler O, Benros ME, Nordentoft M, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry 2014;71(12):1381-91
   PubMed Web of Science ®Google Scholar
• Raison CL, Rutherford RE, Woolwine BJ, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 2013;70(1):31-41
   PubMed Web of Science ®Google Scholar
• Lane RM. Antidepressant drug development: Focus on triple monoamine reuptake inhibition. J Psychopharmacol 2014;29(5):526-44
   PubMed Web of Science ®Google Scholar
• Pae CU. Evidence-based treatment for depressive disorder. Psychiatry Investig 2015;12(2):278-9
   PubMed Web of Science ®Google Scholar
• Han C, Pae CU. Pain and depression: a neurobiological perspective of their relationship. Psychiatry Investig 2015;12(1):1-8
   PubMed Web of Science ®Google Scholar
• Wang SM, Han C, Lee SJ, et al. Vilazodone for the treatment of major depressive disorder: focusing on its clinical studies and mechanism of action. Psychiatry Investig 2015;12(2):155-63
   PubMed Web of Science ®Google Scholar
• Shao L, Li W, Xie Q, et al. Triple reuptake inhibitors: a patent review. (2006 - 2012). Expert Opin Ther Pat 2014;24(2):131-54
   PubMed Web of Science ®Google Scholar
• Monteggia LM, Kavalali ET. Scopolamine and ketamine: evidence of convergence? Biol Psychiatry 2013;74(10):712-13
   PubMed Web of Science ®Google Scholar